Koshinski Asset Management
NBIX icon

Koshinski Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Koshinski Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50
Closed -$4.69K – 1475
2022
Q1 		$4.69K Hold
50
– – ﹤0.01% 1803
2021
Q4 		$4.26K Hold
50
– – ﹤0.01% 1840
2021
Q3 		$4.8K Buy
+50
New +$4.72K ﹤0.01% 1853

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Koshinski Asset Management's NBIX Position: Q2 2022 in Review

Koshinski Asset Management sold out of Neurocrine Biosciences (NBIX) in Q2 2022, closing a stake of 50 shares — an estimated $4.69K sold.

Koshinski Asset Management first reported a position in NBIX in Q3 2021 and held it in 3 quarters. The position peaked at $4.8K in Q3 2021. 437 funds tracked by Wall St. Rank hold NBIX as of Q2 2022.

  • Koshinski Asset Management reported no remaining Neurocrine Biosciences position as of Q2 2022 after selling out during the quarter.
  • Koshinski Asset Management sold 50 Neurocrine Biosciences shares in Q2 2022, an estimated $4.69K.
  • Koshinski Asset Management first reported a position in Neurocrine Biosciences in Q3 2021 and held it in 3 quarters.
  • Koshinski Asset Management's Neurocrine Biosciences position peaked at $4.8K in Q3 2021.
  • 437 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2022.

Based on Koshinski Asset Management's 13F filing for Q2 2022, filed 12 Jul 2022.